MOMO'S BREAKOUT BOARD

[Avoid]

$ADMP +5.75 +2.00 (53.33%)
After Hours: 6.05 +0.30 (5.22%)

Adamis Pharma stock skyrockets after rival EpiPen product gets FDA approval

http://www.marketwatch.com/story/adamis-pharma-stock-skyrockets-after-rival-epipen-product-gets-fda-approval-2017-06-15


Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst

Window of opportunity is still open for Adamis Pharmaceuticals in the $1.2B EpiPen market with their Epinephrine Pre-Filled Syringe product.

The improved EPI PFS design includes features that should allow it to achieve meaningful penetration in both non-retail and consumer markets.

Mylan’s EpiPen pricing and recall mess over the past year has government and consumers demanding that another viable choice be made available.

Adamis has a growing compounding pharmacy business, strong pipeline, increasing institutional ownership, and is fully funded for the next 9-12 months with recent $17M secondary.

Mid-June PDUFA for EPI PFS presents a strong potential catalyst for the stock.

https://seekingalpha.com/article/4078008-adamis-pharmaceuticals-strong-buy-huge-potential-catalyst